Short description

Despite years of research into the efficacy and safety of nanomaterials, their use in medicine remains limited due to insufficient reproducibility of synthesis techniques, relatively high toxicity, and a complex regulatory system in the medical market. Nonetheless, several companies in Europe and Ukraine have established the production of high-purity nanoparticles with reproducible output parameters. The foundation for beginning clinical studies of nanoparticles is experiments to determine biocompatibility and acute toxicity to define the therapeutic application range. The main uses of nanoparticles, especially the creation of antibacterial agents, photothermal therapy for cancer, and drug carriers, are promising for the domestic and foreign medical markets and require comprehensive research involving specialists in biology, biochemistry, medicine, physics, and chemistry. Within the framework of this study, new data regarding the safety of nanoparticles and nanolaminates are planned to be obtained, which will be used for the development of medical devices. A separate issue addressed by the project is the study of the biocompatibility of a new class of nanomaterials – MXenes, which have only recently begun to be used in biomedical research. Given the lack of data on toxicity, biocompatibility, metabolic pathways, and immunogenicity, this research is groundbreaking and opens up new avenues for the application of MXenes in medicine and biology. Establishing the level of toxicity of various compositions of MXenes will lay the foundation for new protocols of photothermal therapy for cancer and targeted drug delivery. Thus, solving the tasks of the project will allow the fundamental bases of the biocompatibility of MXene to be studied, which will open the way to applied research of their use in medical practice.

Proving the working hypothesis regarding determining the safe level of nanoparticles obtained using ‘green synthesis’ technology and establishing the biocompatibility of MXene paves the way for their clinical application both in Ukraine and abroad. The relevance of the planned applied research lies in the existence of close cooperation with leading companies in Ukraine (Carbone Ukraine) and Europe (NanoWave, NanoPrime, Linari Engineering), which opens up prospects for joint commercialization of research results.